Stockreport

BRIEF-Revance’s RT002 Meets Primary, Secondary Endpoints In Sakura Phase 3 Trials [Reuters]

Revance Therapeutics, Inc.  (RVNC) 
Last revance therapeutics, inc. earnings: 2/24 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.revance.com
PDF BRIEF-Revance’s RT002 Meets Primary, Secondary Endpoints In Sakura Phase 3 Trials | Reuters Reuters Staff 1 Min Read Dec 5 (Reuters) - Revance Therapeutics Inc: * REVANC [Read more]